---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000049"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-08-07T20:43:59+00:00"
generated_at: "2026-08-07T20:45:05.763596+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AbCellera to release Phase 2 top-line data for ABCL635 (menopause VMS) on Aug 10, 2026

## Summary
- Top-line data from Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms due to menopause to be released before market open on Monday, August 10, 2026.
- Investor conference call and webcast scheduled at 4:30 a.m. PT / 7:30 a.m. ET on the same day.
- No trial results disclosed in this announcement; data release is upcoming catalyst.

## SEC filing metadata
- accession: 0001703057-26-000049
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-08-07T20:43:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/0001703057-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/abcl-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000049
- JSON: https://secwatch.observer/filing/0001703057-26-000049.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.